GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Femasys Inc (NAS:FEMY) » Definitions » EV-to-EBITDA

Femasys (Femasys) EV-to-EBITDA : -1.28 (As of May. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Femasys EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Femasys's enterprise value is $17.26 Mil. Femasys's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-13.45 Mil. Therefore, Femasys's EV-to-EBITDA for today is -1.28.

The historical rank and industry rank for Femasys's EV-to-EBITDA or its related term are showing as below:

FEMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.88   Med: -0.17   Max: 2.85
Current: -1.27

During the past 5 years, the highest EV-to-EBITDA of Femasys was 2.85. The lowest was -25.88. And the median was -0.17.

FEMY's EV-to-EBITDA is ranked worse than
100% of 487 companies
in the Medical Devices & Instruments industry
Industry Median: 16.43 vs FEMY: -1.27

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-20), Femasys's stock price is $1.26. Femasys's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.840. Therefore, Femasys's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Femasys EV-to-EBITDA Historical Data

The historical data trend for Femasys's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femasys EV-to-EBITDA Chart

Femasys Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - -3.40 0.17 -0.46

Femasys Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 0.26 -3.54 -0.46 -1.73

Competitive Comparison of Femasys's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Femasys's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Femasys's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Femasys's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Femasys's EV-to-EBITDA falls into.



Femasys EV-to-EBITDA Calculation

Femasys's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=17.255/-13.447
=-1.28

Femasys's current Enterprise Value is $17.26 Mil.
Femasys's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Femasys  (NAS:FEMY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Femasys's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.26/-0.840
=At Loss

Femasys's share price for today is $1.26.
Femasys's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.840.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Femasys EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Femasys's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Femasys (Femasys) Business Description

Traded in Other Exchanges
N/A
Address
3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
Executives
Keith J Kendall director 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alistair Milnes director C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Christine E Thomas officer: SVP, Regulatory & Clinical 2836 SW 117TH STREET, GAINESVILLE FL 32606
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Wendy Perrow director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Edward Evantash officer: Chief Medical Officer 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
John Dyett director, 10 percent owner 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025
Adams John Q Jr director 35 WYCK HILL LANE, WESTLAKE TX 76262
Edward R Uzialko director, 10 percent owner 4605 DUDLEY LANE, ATLANTA GA 30327
Charles Larsen director 28 SANDPIPER ROAD, TAMPA FL 33609
Kathy Lee-sepsick director, officer: Chief Executive Officer 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Daniel Scott Currie officer: Senior VP, Operations 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Kelley Hoskin Violet Alexandria officer: VP, Clinical & Medical Affairs 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Gary Thompson director 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
William Benson Witte director 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025